Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
29.71
+0.67 (2.31%)
At close: Nov 3, 2026, 4:00 PM EST
29.76
+0.05 (0.17%)
Pre-market: Nov 4, 2026, 5:57 AM EST
Celldex Therapeutics Analyst Ratings
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy Reiterates $57 | Buy | Reiterates | $57 | +91.85% | Oct 20, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $72 | Buy | Maintains | $72 | +142.34% | Oct 15, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $61 → $72 | Buy | Maintains | $61 → $72 | +142.34% | Oct 14, 2026 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $38 → $28 | Hold | Maintains | $38 → $28 | -5.76% | Oct 5, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $64 | Buy | Reiterates | $64 | +115.42% | Oct 5, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Maintains $56 → $64 | Buy | Maintains | $56 → $64 | +115.42% | Oct 3, 2026 |
| Leerink Partners | Leerink Partners | Buy Reiterates $70 → $88 | Buy | Reiterates | $70 → $88 | +196.20% | Sep 23, 2026 |
| Guggenheim | Guggenheim | Buy Reiterates $100 | Buy | Reiterates | $100 | +236.59% | Sep 23, 2026 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 3 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.